Stephanie M. Hastings

IP25-18 PROSTATE CANCER SCREENING PATTERNS BETWEEN INTERNAL MEDICINE AND FAMILY MEDICINE-TRAINED PRIMARY CARE PHYSICIANS: A RETROSPECTIVE COHORT STUDY

Eric J. Macdonald, Rumel Mahmood, Benjamin Green, Andrew Williams et autres

IP62-28 FROM DNA TO DECISION: THE SYNERGY OF GERMLINE AND SOMATIC TESTING IN PROSTATE CANCER

Sarah M. Nielsen, Neal D. Shore, Emily M. Russell, Michelle Green et autres

Abstract 1075: Comparison of tissue and liquid biopsy CGP in advanced solid tumors: Insights from a community cancer center

Padmapriya Swaminathan, McKenna Perrin, Crystal Hattum, Stephanie M. Hastings et autres

Abstract Introduction: Next-generation sequencing (NGS) tumor profiling is a mainstay for guiding therapy in oncology. Circulating tumor DNA (ctDNA) testing offers an additional, minimally invasive approach of detecting actionable alterations. We evaluated the concordance between solid tissue and liquid biopsy comprehensive genomic …

us (code pays fourni par la source)

Abstract 653: Rapid drug sensitivity testing of passage-zero patient brain tumor tissues to inform preclinical and clinical decisions: results from a clinical feasibility study.

Breanna Mann, Nichole Artz, Adebimpe Adefolaju, Alain Valdivia et autres

Abstract Functional precision medicine (FPM) offers a promising path forward in neuro-oncology, where genomic profiling alone often fails to predict therapeutic response. To bridge this gap, we developed the Screening Live Cancer Explants (SLiCE) platform, a rapid ex vivo drug screening assay …

us (code pays fourni par la source)

Machine Learning Algorithm for the Detection of Tumor Microsatellite Instability Based on Multiomics Biomarkers

Kyle C. Strickland, Zachary D. Wallen, Sarabjot Pabla, Heidi Chwan Ko et autres

PURPOSE: Accurate classification of microsatellite instability (MSI) in advanced cancers is critical for identifying patients who may benefit from immune checkpoint inhibitors. However, variability in MSI detection workflows can lead to missed MSI-high cases, indicating need for complementary screening approaches. Using next-generation …

us (code pays fourni par la source)

Rapid Functional Drug Screening of Passage-Zero Patient Brain Tumor Tissues Ex Vivo: Results from a Clinical Feasibility Study

Andrew Satterlee, Breanna Mann, Nichole Artz, Adebimpe Adefolaju et autres

us (code pays fourni par la source)

Correction: RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer

Kyle C. Strickland, Zachary D. Wallen, Heidi Chwan Ko, Michelle F. Green et autres

The original version of this Article contained an error where an incorrect version of Fig. 3 was published. The original Fig. 3 and accompanying legend appear below. Fig. 3 Genomic landscape of cases from the OmniSeq HGSOC cohort. The histogram below shows …

us (code pays fourni par la source)

RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer

Kyle C. Strickland, Zachary D. Wallen, Heidi Chwan Ko, Michelle F. Green et autres

High-grade serous ovarian carcinoma (HGSOC) is a molecularly heterogeneous and lethal malignancy, with late-stage diagnosis contributing to high risk of recurrence and poor clinical outcomes. Although homologous recombination (HR) deficiency and retinoblastoma gene (RB1) expression have been implicated in prognosis, their combined …

us (code pays fourni par la source)

RB1 expression and HR proficiency define a poor-outcome molecular subtype of high grade serous ovarian carcinoma

Kyle C. Strickland, Zachary D. Wallen, Heidi Chwan Ko, Michelle F. Green et autres

us (code pays fourni par la source)

RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting

Zachary D. Wallen, Marni Brisson Tierno, Erica K. Schnettler, Alison Roos et autres

Introduction NTRK1, NTRK2, and NTRK3 gene fusions are rare oncogenic driver alterations found in diverse tumor types of adults and children. They are clinically important biomarkers as tumors harboring these genomic alterations have high response rates to targeted therapy. Routine testing for …

us (code pays fourni par la source)

64. A rare finding of triple KRAS mutations with OmniSeq® INSIGHT in a patient with colorectal adenocarcinoma

Durga Prasad Dash, Eric Allan Severson, Kyle C. Strickland, Heidi Chwan Ko et autres

us (code pays fourni par la source)

Abstract PO4-25-03: Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer

Robert D. Seager, Heidi Chwan Ko, Sarabjot Pabla, Maria-Fernanda Senosain et autres

Abstract Background: KEYNOTE-522 has resulted in FDA approval of the immune checkpoint blocker pembrolizumab with neoadjuvant chemotherapy for patients with high-risk triple negative breast cancer (TNBC), given the remarkable improvement in pCR rate to 65% along with improvement in event free survival, …

us (code pays fourni par la source)